Sandoz Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars. Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the name Sandoz.

Revenue(RF), mln.USD
312
Assets(RF), mln.USD
198
Capital(RF), mln.USD
78
Staff(RF), 2021
1088
The Company Statement
April 05, 2024

Have decided to suspend any investment in Russia as well as commercial marketing activities. The company did not stop working in Russia. The Russian website is working. In October 2023, the general director was changed. Staff are being recruited.

March 22, 2024Job opening for Sandoz registration specialist in Moscow
October 02, 2023Anna Bochkareva has been appointed General Director of Sandoz in Russia from October 1, 2023
March 04, 2022Novartis condemns the war in Ukraine and commits to supporting humanitarian efforts
All company names used on this web page are for identification purposes only. All trademarks and registered trademarks are the property of their respective owners.
Company statements and statistical data are collected from open sources and official registers according to the methodology of the KSE Institute.
Scanner